Mylan Biocon

Showing 1 posts of 1 posts found.

fda2outsideweb

Mylan and Biocon’s Semglee, biosimilar to Sanofi’s Lantus, approved by FDA for type 1 and 2 diabetes

June 12, 2020
Medical Communications, Sales and Marketing FDA, Lantus, Mylan Biocon, Sanofi, Semglee, diabetes

Mylan and Biocon have scored FDA approval with their insulin glargine injection Semglee, a biosimilar to Sanofi’s Lantus, in both …

Latest content